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ABSTRACT
Psychotic fear and anxiety disturbances are seen at a relatively high frequency in patients with schizophrenia. Atypical antipsychotics are believed to show superior efficacy in reducing these symptoms. However, clinical and preclinical evidence
regarding their anxiolytic efficacy has been mixed. In this study, we evaluated the possible anxiolytic property of two atypicals, clozapine and olanzapine, and compared them with typical haloperidol and chlordiazepoxide (a prototype of sedative-anxiolytic drug) in two preclinical models of fear. In Experiment 1, we used a fear-induced passive avoidance and conditioned place aversion paradigm and examined the effects of clozapine (20 mg/kg, sc), haloperidol (0.05 mg/kg, sc) and
chlordiazepoxide (10mg/kg, ip). In Experiments 2 and 3, we used a two-way active avoidance conditioning paradigm and
further compared the effects of clozapine (20 mg/kg, sc), haloperidol (0.05 mg/kg, sc), chlordiazepoxide(10mg/kg, ip) and
three doses of olanzapine (0.5, 1.0, and 2.0 mg/kg, sc). Results show that clozapine and chlordiazepoxide, but not haloperidol, significantly attenuated the shock conditioning-induced place aversion, decreased the amount of defecations and the
number of the 22-kHz vocalizations. Clozapine also reduced the shock conditioning-induced hyperthermia. Similar to clozapine, olanzapine also significantly decreased the amount of defecations and reduced the shock conditioning-induced
hyperthermia, but it did not inhibit the 22-kHz vocalizations. This study demonstrates that clozapine and olanzapine possess an intrinsic anxiolytic property, which is not attributable to its superior anti-“psychotic” effect or its favorable effects
on motor functions or learning and memory processes. These findings also suggest that the combined use of passive avoidance and active avoidance conditioning models can be useful in better differentiating typical and atypical anti-psychotics
as well as anxiolytics.

1. Introduction
In recent years, atypical anti-psychotic drugs (APDs) such as risperidone, olanzapine and quetiapine have been increasingly used to
treat anxiety-related disorders in addition to their use in the treatment of psychosis. The results have been mixed (Carson et al., 2004).
Some case reports suggest that atypicals improve symptoms of
obsessive-compulsive disorder and panic disorder, while an equal
number of reports indicate the worsening effects on these disorders
(Brooke et al., 2005). Preclinical evidence is also inconclusive. Some
studies have demonstrated ananxiolytic-like activity with the atypicals. For example, clozapine is reported to be effective in attenuating shock-induced conditioned freezing (Inoue et al., 1996; IshidaTokuda et al., 1996), footshock-induced ultrasonic vocalization
(DeVry et al., 1993), passive avoidance response (Rasmussen et al.,
2001) and increasing time spent in the central area of an open field
(Bruhwyler et al., 1990b). It has also been found that clozapine can
produce a significant increase in responding during the conflict com-

ponent of a modified Geller-Seifter operant procedure, while typicals such as haloperidol, chlorpromazine, and thioridazine did not
(Wiley et al., 1993). The ability of clozapine to increase punished
responding has also been found in pigeons (Mansbach et al., 1988),
mice and squirrel monkeys (Spealman and Katz, 1980), suggesting
it may possess some anxiolytic activity. Olanzapine is found to be
effective in reducing conditioned freezing, in increasing time spent
on the open arms of the elevated plus maze as well as that in social
interaction (Frye and Seliga, 2003) and indecreasing stress-induced
ultrasonic vocalizations (Siemiatkowski et al., 2001). Both olanzapine and clozapine have been found to increase water licking of an
electrified water bottle in the Geller-Seifter conflict task (Moore et
al., 1992), demonstrating that these atypical anti-psychotics may possess anxiolytic activity. However, there are other reports that fail to
confirm this anxiolytic activity (Cao and Rodgers, 1997; FernandezTome et al., 1979; Masson et al., 2003; Shadach et al., 1999). Still others
even suggest an anxiogenic activity (Karl et al., 2006; Manzaneque et
al., 2002). This issue is further complicated by other studies show-
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ing that even typical APDs also display ananxiolytic property in
the same behavioral paradigms mentioned above (Allen et al., 1974;
Greba et al., 2001; Guarraci et al., 2000; Inoue et al., 2005; Inoue et al.,
1996; Johnson, 1970a, b; Joordens et al., 1998; Olivier et al., 2003; Ponnusamy et al., 2005; Taukulis et al., 1992).
Other than the procedural differences (species, drug doses, timing of drug administrations, etc.), several factors may also account
for this rather confusing group of studies. First, a wide variety of
behavioral models including both unconditioned (e.g., elevated
plus maze, open field) and conditioned fear paradigms (e.g., conditioned freezing, fear-potentiated startle) have been used, which
may not measure the same aspects of fear/anxiety responses and
may not provide the same assessment of the drug effects. Furthermore, most studies often employ just one behavioral task or measure, rather than a series of convergent tasks and measurements to
cross-validate the findings. Second, all APDs have multiple behavioral actions (e.g., motor, emotion, motivation or even cognition),
the interactions among which may mask the effect size of one specific effect and influence the way we interpret the data. Finally, the
intrinsic anti-psychotic effect of the drugs may also impact the measurements of anxiolytic activity, and most previous studies have not
carefully controlled this influence. Therefore, clinical and preclinical evidence accumulated so far is inadequate to assess the intrinsic anxiolytic property of both typical and atypical APDs, and the
possible advantages of atypicals over typicals in the treatment of
anxiety disorders or anxiety in schizophrenia have not been determined.
In light of these observations, the present study further investigated the possible anxiolytic property of typical and atypical APDs
using a preclinical approach. Specifically, in Experiment 1, we
used a composite passive avoidance and conditioned place aversion task and examined the effects of acute treatment with clozapine, haloperidol or chlordiazepoxide (one single injection) on various conditioned fear responses (e.g. inhibitory passive avoidance,
ratio of time spent in the shock compartment relative to time in the
safe compartment, etc.). Haloperidol and clozapine were chosen
as the representatives of typical and atypical APDs. Chlordiazepoxide was chosen as the representative of classic benzodiazepine
anxiolytics. In Experiment 2, using an active avoidance conditioning model (CAR), we compared the effects of repeated treatment
with these drugs (7 daily repeated injections) on the conditioned
active avoidance response as well as other associated conditioned
fear responses (amount of defecation, ultrasonic vocalization,
change in body temperature) to cross-validate the results from
Experiment 1 and to extend them to a repeated treatment regimen.
The CAR model was carefully selected because it is a well-established model for the study of anti-psychotic activity (Wadenberg
and Hicks, 1999). All currently used APDs selectively inhibit conditioned avoidance responding but not escape, whereas anxiolytics
or antidepressants do not have such selectivity (Arnt, 1982). More
importantly, in addition to robust avoidance responding, animals
tested in this model also show various signs of fear and anxiety,
such as increased body temperature, emission of ultrasonic vocalization (termed 22-kHz calls), and defecation and urination, which
have been routinely used as reliable measures of conditioned reactive fear as well as to assess anxiolytic properties of psychotropic
drugs (DeVry et al., 1993; Fanselow, 1986; Godsil et al., 2000; Sanchez, 2003). Thus we were able to use this single behavioral paradigm to compare the anxiolytic property of typical and atypical
APDs (as indexed by their action on various fear responses), while
properly matching their anti-psychotic property (as indexed by their
action on active avoidance responding). This latter point is particularly important because one of the problems in previous drug comparison studies is that the typical APDs and atypicals often were not
compared under the same conditions, with the doses for the typicals substantially higher than those of atypicals (Siemiatkowski et
al., 2001) in terms of their efficacy to produce a clinically comparable level of D2 receptor occupancy (60-80%) (Kapur et al., 2003b) and
to disrupt avoidance responding to the same extent (Li et al., 2007);

Mead, Li & Kapur in Pharmacology, Biochemistry and Behavior 90 (2008)

thus, any beneficial effect resulting from the atypicals may simply
be attributed to the dose differences. In Experiment 3, using the
same paradigm and fear response measures as used in Experiment
2, we investigated the potential anxiolytic property of olanzapine,
another atypical APD with a similar profile to clozapine, but much
more widely used than clozapine, to further examine this issue. We
also employed 3 different doses of olanzapine to examine any dosedependent effects of the most clinically relevant atypical.
2. Materials and methods
2.1.Subjects
Sixty male Sprague-Dawley rats (275-325 g upon arrival, Charles
River, Montréal, Canada) were used in Experiment 1, 44 male rats
(250-275 g upon arrival, Charles River, Potage, MI) were used in
Experiment 2, and 45 male rats (250-275 g upon arrival, Charles
River, Potage, MI) were used in Experiment 3. They were housed
two per cage, in 48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate cages under 12-h light/dark conditions (light on between 8:00
p.m. and 8:00 a.m. in Experiment 1, and between 6:00 a.m. and 6:00
p.m. in Experiments 2 and 3). Room temperature was maintained at
21 ± 1° with a relative humidity of 55-60%. Food and water was available ad libitum. Animals were allowed at least one week of habituation to the animal facility before being used in experiments. All procedures were approved by the animal care committees at either the
Centre for Addiction and Mental Health (for Experiment 1) or the
University of Nebraska-Lincoln (for Experiments 2 and 3).
2.2. Apparatus
Two identical two-way shuttle boxes custom designed and manufactured by Med Associates (St. Albans, VT) were used. Each box
was housed in a ventilated, sound-insulated isolation cubicle (96.52
cm W × 35.56 cm D × 63.5 cm H). Each box was 64 cm long, 30 cm
high (from grid floor) and 24 cm wide, and divided into two equalsized compartments by an automatic guillotine door (ENV-010B,
Experiment 1) or a white PVC partition with an arch style doorway (15 cm high × 9 cm wide at base, Experiments 2 and 3). The
grid floor consisted of 40 stainless steel rods with a diameter of 0.48
cm, spaced 1.6 cm apart center to center, through which scrambled
footshock (US, 0.8 mA) was delivered by a constant current shock
generator (Model ENV-410B) and scrambler (Model ENV-412). For
Experiments 2 and 3, illumination was provided by two houselights (28V) mounted at the top of each compartment. An ultrasonic vocalization detector (ANL-937A) was situated on the right
side wall of each box. The rat location and locomotor activity was
detected by a set of 16 photobeams (ENV-256-8P) affixed at the bottom of the box (3.5 cm above the grid floor). The CS was a 74-dB
white noise produced by a speaker (ENV224 AMX) mounted on the
ceiling of the cubicle, centered above the shuttle box. All the training and testing procedures were controlled by Med Associates programs running on a computer. Background noise (approximately
68 dB) was provided by a ventilation fan affixed at the top corner of
each isolation cubicle.
2.3. Drugs and choice of doses
Haloperidol (HAL), 5 mg/ml ampoules (Sabex Inc. Boucheville,
Quebec, Canada), clozapine (CLZ, gift from National Institute of
Mental Health’s Chemical Synthesis and Drug Supply Program
or from Anawa Biomedical Services and Products, Zurich, Switzerland), olanzapine (OLZ, purchased from Toronto Chemicals
Inc., Ontario, Canada), and chlordiazepoxide (CDP, Sigma Chemical, St. Louis, MO) were used. The injection solutions of haloperidol and chlordiazepoxide were obtained by mixing the drugs with
sterile water. Clozapine and olanzapine were dissolved in 1-2% glacial acetic acid in sterile water. The doses of haloperidol (0.05 mg/
kg), clozapine (20 mg/kg) and olanzapine (0.5, 1.0, and 2.0 mg/kg)
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were chosen based on the following considerations: (1) Our previous
report shows that at these doses, haloperidol, clozapine and olanzapine produced a comparable level of disruption on the acquisition and extinction of avoidance responding, a validated behavioral
index of anti-psychotic activity, but had no effect on escape (Li et
al., 2007; Li et al., 2004); (2) all three drugs at these doses also gave
rise to 50%-70% striatal dopamine D2 occupancy in rats comparable
to those observed in schizophrenic patients (Kapur et al., 2003a), so
these doses were considered clinically relevant. The dose of chlordiazepoxide (10 mg/kg) was chosen on the basis of the fact that it is
an effective dose in other aversively conditioned paradigms, such
as Pavlovian fear conditioning and passive avoidance responding
(Joordens et al., 1998; Klint, 1991; Nabeshima et al., 1990; Sanger and
Joly, 1985; Tohyama et al., 1991).
2.4. Statistical analysis
Passive avoidance latency data and the relative time ratio data
were expressed as median ± interquartile ranges because they were
not normally distributed due to ceiling effects, and thus could not be
analyzed using parametric tests. These data were analyzed using the
nonparametric Kruskal-Wallis test (>3 groups) or Mann-Whitney
U test (Decker et al., 1990). Within-group comparisons across days
were performed using Friedman Test (for more than 3 related samples) or Wilcoxon Signed Ranks Test (for 2 related samples).
Parametric data such as number of avoidance responses, amount
of defecations, and body temperature change were expressed as
mean values ± SEM and were analyzed using a factorial repeated
measures analysis of variance (ANOVA) with the between-subjects
factor being treatment condition (“Treatment,” e.g. haloperidol, clozapine, etc.) and the within-subject factor being the test sessions
(“Session,” e.g. day 1 test, day 2 test, etc.) and Post hoc Tukey HSD
tests were used to identify the overall group differences. If necessary, one-way ANOVAs were used to identify the group differences
on each test session. A conventional two-tailed level of significance
at the 5% level was required.
2.5. Experiment 1: effects of acute haloperidol, clozapine or chlordiazepoxide treatment on the acquisition of passive avoidance and conditioned place
aversion
This experiment was aimed to characterize the behavioral effects
of acute treatment with haloperidol, clozapine and chlordiazepoxide treatment on various conditioned fear responses in a composite
passive avoidance and conditioned place aversion task, two traditional behavioral tests that have been widely used to assess anxiolytic activity of a drug (Papp, 1988; Sanger and Joly, 1985). This
task encompasses multiple measures indicative of conditioned
fear, including passive avoidance response (e.g. passive avoidance
latency and number of entries to the shock compartment), conditioned place aversion (e.g. the ratio of time spent in the shock compartment relative to the time spent in the safe compartment), and
defecations.
2.5.1. Procedure
A total of 60 rats were randomly assigned to the following 4
groups: haloperidol, clozapine, chlordiazepoxide or vehicle groups.
There were 15 rats in each group.
2.5.1.1. Baseline test (habituation). After receiving 5 days of handling
(approximately 1 min/rat), subjects were placed into the shuttle
boxes for the baseline test and habituation. The left compartment
of the shuttle box was decorated with 2-cm horizontal tape stripes
on the back and front walls and the ceiling, while the right compartment was decorated with vertical stripes, with an automatic guillotine door (ENV-010B) sitting in between. The left compartment also
had a lightbulb (28 V) in the middle of the sidewall providing illumination. A subject was first placed in the left compartment (“safe”) at
the beginning of the test. Thirty seconds later, the door was lifted and
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the subject was allowed to enter the right compartment and explore
the whole apparatus for 10 min. The latency to enter the right compartment, time spent in each compartment, number of entries to the
right compartment, and numbers of defecations were recorded.
2.5.1.2.Conditioning (under drug). On the next day, the subject was
placed in the left compartment of the shuttle box after receiving
HAL (0.05 mg/kg, -90 min.), CLZ (20 mg/kg, -30min.), CDP (10 mg/
kg, -30 min.) or vehicle injection (distilled water, -90 min.). Thirty
seconds later, the door was lifted and the subject was allowed to
enter the right compartment. Once entered, the door was immediately closed and 10 trials of CS-US were given. The CS was 11 s, 10
kHz, 85 dB pure tone, while the US was 1 s, 0.8 mA footshock. The
onset of the US occurred 10 s after the onset of the CS andco-terminated with the CS. The mean intertrial interval was 60 s (40-80s).
2.5.1.3. Post-conditioning test (without drug). Two days after the conditioning, the test was conducted. The basic procedure was exactly
the same as the baseline test (see Baseline test above) and lasted 10
min. Similarly, the latency to enter the shock compartment (passive avoidance latency), time spent in each compartment (max 600
s), number of entries to the shock compartment, and the numbers
of defecations were recorded. If the subject failed to enter the right
compartment within 10 min., a latency of 600 s was assigned.
2.6. Experiment 2: effects of repeated haloperidol, clozapine or chlordiazepoxide treatment on conditioned active avoidance responding and various
conditioned fear responses
To cross-validate the anxiolytic effects of clozapine and chlordiazepoxide observed in Experiment 1, this second experiment used an
active avoidance conditioning model and examined how repeated
haloperidol, clozapine or chlordiazepoxide treatment (7 consecutive
days) differentially affected various conditioned fear responses in
this model, such as body temperature change (before and after conditioning), 22-kHz USVs, and amount of defections, along with their
effects on active avoidance responding, an index of an anti-psychotic
property. This model allowed us to concurrently evaluate and compare the anti-psychotic and potential anxiolytic activities of haloperidol and clozapine.
2.6.1. Procedure
In order to adapt rats to the body temperature measuring procedure and injection procedure and to minimize the associated stress,
all rats were first handled daily and habituated to the body temperature measuring procedure (twice daily, 20 min interval) and injection procedure for 6 successive days, which was sufficient to obtain
a stable baseline body temperature (Godsil et al., 2000). Following
this adaptation phase, all rats were habituated to the CAR boxes for
2 days (20 min./day) and their body temperatures (twice: before and
after habituation) and amount of defecations (in mg) were recorded.
In addition, the “22-kHz” ultrasonic vocalizations (USVs) were also
recorded. After the habituation, the rats were randomly assigned to 5
groups: haloperidol (HAL, n = 9), clozapine (CLZ , n = 10), chlordiazepoxide (CDP, n = 10), vehicle (VEH, n = 9) and control (CON, n = 6).
In the subsequent 7 days, the first 4 groups were trained in a 20-trial
CAR session/day, whereas the control group continued on the 20
min. habituation procedure (no CS or US). Before each daily session,
the rats were injected with HAL (0.05 mg/kg, sc), CLZ (20 mg/kg,
sc), CDP (10 mg/kg, ip) or vehicle (sterile water for both VEH and
CON groups, ip or sc), and their body temperatures were recorded
before being placed in the boxes. HAL and CLZ were administered
1 h before the training, whereas CDP was administered 0.5 h before.
Body temperatures were taken again immediately after each test.
Following the 7 daily drug tests, all rats were continuously tested
drug-free for an additional 3 sessions under the CS-only condition
(no US) to assess the long-term drug effects not contaminated by the
presence of the shock or during the extinction phase. Table 1 summarizes the experimental procedure.
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3. Results
3.1. Experiment 1: effects of acute haloperidol, clozapine or chlordiazepoxide treatment on the acquisition of passive avoidance and conditioned place
aversion

2.6.1.1. Two-way active avoidance training (under drug). Every trial
started by presenting the CS for 10 s, followed by a continuous
scrambled footshock (0.8 mA, US, maximum 5 s) on the grid floor.
If a subject moved from one compartment in to the other within
the 10 s of CS presentation, it avoided the shock, and this shuttling
response was recorded as avoidance. If the rat remained in the same
compartment for more than 10 s and made a crossing upon receiving the footshock, this response was recorded as escape. If the animal did not respond during the entire 5 s presentation of the shock,
the trial was terminated and escape failure was recorded. Intertrial
intervals varied randomly between 30 and 60 s. Each training session
lasted about 20 min with a total of 20 trials presented. The number of
avoidance responses (max: 20) was calculated as the main dependent
variable for avoidance responding. Fecal matter was collected and
weighed on a Mettler Toledo scale (< 0.1 mg). An ultrasonic vocalization detector (model number: ANL-937-1) recorded the ultrasonic
events throughout each session. This detector scans the environment
every 30 ms and counts any vocalization call with a minimum duration of 30 ms. We chose to record “22-kHz” calls occurring between
20 kHz and 32 kHz and above 50 dB because vocalizations within
this range are often found in rats that are exposed to fearful stimli
(Wohr et al., 2005) and are sensitive to anxiolytic treatments (Sanchez, 2003). The rat’s body temperature was taken using a probe
(lubricated with mineral oil) inserted in the rectum (Thermalert
TH-5, Physitemp, Clifton, NJ, USA) before and after the behavioral
training/testing and the difference was calculated. The thermistor is
accurate to 0.1°C.
2.6.1.2. Two-way active avoidance test (drug-free). One day after the last
training session, all rats were continuously tested drug-free for an
additional 3 sessions under the CS-alone (no shock) condition. The
exact same procedure was employed except that the footshock was
omitted.
2.7. Experiment 3: effects of repeated olanzapine or chlordiazepoxide treatment on conditioned active avoidance responding and various conditioned
fear responses
The purpose of this experiment was to determine the potential
anxiolytic effect of olanzapine, a much more widely used drug in
the clinic. This experiment also used the active avoidance conditioning model to examine how repeated olanzapine or chlordiazepoxide
treatment differentially affected various conditioned fear responses
in this model. We employed three doses of olanzapine which covered subclinical, clinical and superclinical doses of olanzapine in
terms of D2 receptor occupancy (50%-80%) to explore its dose-dependent effect (Kapur et al., 2003b).
2.7.1. Procedure
The exact same procedure as used in Experiment 2 was used. After
the habituation, the rats were randomly assigned to 5 groups: vehicle (VEH, n = 9), olanzapine 0.5 mg/kg (OLZ 0.5, n = 9), olanzapine
1.0 mg/kg (OLZ 1.0, n = 9), olanzapine 2.0 mg/kg (OLZ 2.0, n = 9)
and chlordiazepoxide 10 mg/kg (CDP, n = 9) and tested for 7 days
under drug and 3 days under drug-free.

Haloperidol significantly increased, while chlordiazepoxide significantly decreased the passive avoidance latency. On the baseline
test day and the conditioning day, the latencies to enter the right (“to
be shocked”) compartment were similar among the 4 groups (all ps >
0.056, data not shown). However, the passive avoidance latencies on
the test day were significantly different among the haloperidol, clozapine, chlordiazepoxide and vehicle-treated groups (Kruskal-Wallis tests, p = 0.004). In comparison to the vehicle, chlordiazepoxide
significantly decreased the passive avoidance latency (Mann-Whitney U test, U = 65.50, p = 0.050), whereas haloperidol significantly
increased it (U = 65.50, p = 0.050). Clozapine had no significant effect
on this measure (U = 99.00, p > 0.59). As can be seen in Figure 1,
when compared to the baseline measures, the passive avoidance
latencies in both the haloperidol and vehicle groups showed a significant increase from the baseline day to the test day (Wilcoxon Signed
Ranks Test, all ps < 0.013). In contrast, the clozapine and chlordiazepoxide groups did not show such a significant change (p = 0.069
for CLZ and p = 0.91 for CDP), indicating that the inhibitory passive
avoidance to the shock compartment was attenuated by chlordiazepoxide and, to some extent, by clozapine.
Clozapine and chlordiazepoxide, but not haloperidol, significantly attenuated the shock conditioning-induced place aversion. Figure 2 shows the
median ratios of the time spent in the shock compartment relative
to the time spent in the safe compartment (Figure 2A) and the mean
numbers of entries into the shock compartment (Figure 2B) on both
the baseline habituation day and the post-conditioning test day.
These two behaviors provide reliable indices of the shock-induced
conditioned place aversion effect (DiScala and Sandner, 1989; Holahan and White, 2004). Clozapine and chlordiazepoxide exhibited a
very similar behavioral profile on these two measures. In comparison to vehicle treatment, both clozapine and chlordiazepoxide significantly attenuated the shock conditioning-induced decrease on the
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T-Tests, all ps < 0.015), suggesting that rats did acquire conditioned
fear after conditioning. In comparison to the vehicle group, defecations in both the clozapine and chlordiazepoxide groups were significantly decreased on the conditioning day (Tukey Post hoc, p = 0.000
for CLZ and 0.041 for CDP), and chlordiazepoxide also decreased
defecations on the test day (p = 0.016).
3.2. Experiment 2: effects of repeated haloperidol, clozapine or chlordiazepoxide treatment on active avoidance responding and various conditioned
fear responses
Repeated haloperidol and clozapine, but not chlordiazepoxide treatment significantly inhibited avoidance responding during the CAR training phase. Figure 4A shows the number of conditioned avoidance
responses in the four groups trained under the drug or vehicle over
the 7 training days. Both the vehicle and chlordiazepoxide-treated
rats, but not the haloperidol or clozapine rats, showed a progressive
across-session increase in avoidance responding, indicating a clear
learning effect (Repeated Measures ANOVAs: a significant main
effect of “Treatment”: F(3,34) = 16.011, p < 0.001; “Sessions”: F(6,204) =
16.822, p < 0.001; and “Treatment” × “Sessions” interaction, F(18,204)
= 4.761, p < 0.001). In comparison to the vehicle treatment, haloperidol and clozapine, but not chlordiazepoxide, significantly inhibited
the acquisition of avoidance responding (Tukey Post hoc Tests: HAL
vs. VEH, p < 0.001; CLZ vs. VEH, p = 0.001; CDP vs. VEH, p = 0.818).
Most importantly, both drugs did not differ in the magnitude of their
inhibition during the drug test days (Tukey HSD, p = 0.950), suggesting that at the chosen doses, they exhibited a very similar level of
anti-psychotic efficacy as this measure is a reliable and sensitive predictor of anti-psychotic efficacy (Wadenberg and Hicks, 1999).
Figure 4B shows the number of conditioned avoidance responses
in the three drug-free and CS-alone test days (i.e. extinction). The
haloperidol group still exhibited significantly lower numbers of
avoidances than the vehicle group on day 1 (p = 0.008), whereas the
clozapine group did not (p > 0.270). Data from the clozapine group in
both the drug training days and the drug-free test days suggest that
clozapine did not impair the animals’ ability to learn how to actively
respond to the aversive CS, but only inhibited its expression.
Clozapine and chlordiazepoxide, but not haloperidol, inhibited the
expression of 22-kHz ultrasonic vocalizations. As can be seen from Figure 5, during the 2 habituation days, there were few vocalizations
recorded. During the 7 CAR training days, only the chlordiazepoxide group showed a progressive decrease in the number of 22-kHz
calls. The haloperidol group had consistently high levels of 22-kHz
calls, whereas the clozapine group showed consistently lower levels of 22-kHz calls (“Treatment”: F(4,39) = 11.371, p < 0.001; “Sessions”:
F(6,234) = 2.657, p = 0.016; “Treatment” × “Sessions” interaction, F(24,234)
= 3.745, p < 0.001). On the first drug test day, clozapine significantly

time spent in the shock compartment (U = 43.00, p = 0.003 for CLZ;
U = 42.00, p = 0.003 for CDP) and the number of entries into the
shock compartment on the test day (Tukey Post hoc p = 0.031 and
0.001 for CLZ and CDP). Haloperidol had little effect (all ps > 0.36).
Compared to the baseline measures, although the vehicle and haloperidol-treated rats decreased their time spent in the shock compartment after conditioning (Wilcoxon Signed Ranks Test, p = 0.011
for the vehicle and p = 0.002 for the haloperidol), the clozapine and
chlordiazepoxide rats did not (all ps >0.06).
Clozapine and chlordiazepoxide, but not haloperidol, significantly attenuated the shock conditioning-induced increase in defecations. Figure 3
shows the number of defecations across the baseline, conditioning
and test days. In comparison to the baseline, all four groups showed
a significant increase in defecations on the test day (Paired samples
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decreased the 22-kHz calls (p = 0.035 vs. VEH). In comparison to the
“unconditioned” control group, all conditioned groups showed significantly higher numbers of 22-kHz calls during certain drug test
days (Individual Repeated Measures ANOVAs, all ps < 0.01), suggesting that the footshock did cause fear or anxiety in these groups
(Wohr et al., 2005). Importantly, during the subsequent 3 drugfree test days, rats that were previously treated with clozapine and
chlordiazepoxide still made significantly less 22-kHz calls than did
the vehicle rats (CLZ: F(1,17) = 7.039, p = 0.017; CDP: F(1,17) = 8.114, p =
0.011), and their numbers of the 22-kHz calls were not significantly
different from the “unconditioned” controls (all ps > 0.756). Haloperidol rats, like the vehicle controls, still exhibited more 22-kHz
calls than the “unconditioned” controls (day 1: ps < 0.031; day 2: ps
< 0.018; day 3: p = 0.42 for VEH and 0.58 for HAL). Because no shock
was ever presented at this test stage, these 22-kHz calls could be considered as an acquired “conditioned fear response” to the CS and/or
to the environment. These results suggest that clozapine and chlordiazepoxide, but not haloperidol, do possess an anxiolytic property in
decreasing this particular conditioned fear response.
Clozapine and chlordiazepoxide inhibited the physiological fear responses
(e.g. body temperature increase and defecations). Stress-induced hyperthermia and defecation is an integral part of an individual’s physiological response to threatening situations and have been used as
valid tools to screen chemical compounds with anxiolytic property
(Bruhwyler et al., 1990a; Olivier et al., 2003). Figures 6A and B depict
the body temperature changes (before and after testing) and the
amounts of defecation that the rats made throughout the habituation, CAR training and drug-free test phases. During the habituation
period, both measures remained low, and no significant group difference was detected (all ps > 0.05). During the CAR training phase, the
clozapine and “unconditioned” control groups did not show much
change in either measure from the habituation days, whereas the
other three groups increased their body temperatures and amount of
defecations. Throughout the training sessions, all groups except the
clozapine group showed a relatively stable level of hyperthermia. On
the measure of defecations, the haloperidol group appeared to defecate more over the sessions, whereas the vehicle and chlordiazepoxide groups defecated progressively less. Repeated Measures ANOVAs indicated a significant effect of “Treatment” (body temperature:
F(4,39) = 18.334, p < 0.001; defecations: F(4,39) = 27.033, p < 0.001), “Sessions” (body temperature: F(6,234) = 3.861, p = 0.001; defecations: F(6,234)
= 3.977, p = 0.001) and “Treatment” × “Sessions” interactions (body
temperature: F(24,234) = 3.618, p < 0.001; defecations: F(24,234) = 2.653, p <
0.001). In comparison to the vehicle treatment, clozapine treatment
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significantly inhibited hyperthermia (p < 0.001), and both clozapine
(p < 0.001) and chlordiazepoxide treatment (p = 0.007) also significantly inhibited defecations. In contrast, haloperidol treatment did
not affect hyperthermia, but did increase the amount of defecation
on the last training day compared to the vehicle group (p = 0.010).
During the drug-free test phase, although both clozapine and
chlordiazepoxide-treated rats seemed to defecate less, while the
haloperidol-treated rats defecated more in comparison to the vehicle
rats, these effects failed to reach a significant level (all ps > 0.05).
3.3. Experiment 3: effects of repeated dose-dependent olanzapine or chlordiazepoxide treatment on conditioned active avoidance responding and various conditioned fear responses
Repeated oanzapine treatment, but not chlordiazepoxide, significantly
inhibited avoidance responding during the CAR training phase and drugfree test phase. Figure 7A shows the number of conditioned avoidance
responses in the five groups for the 7 training days. Both the vehicle
and chlordiazepoxide-treated rats, but not the olanzapine-treated
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rats, showed a progressive across-session increase in avoidance
responding, indicating a clear learning effect (Repeated Measures
ANOVAs: a significant main effect of “Treatment”: F(4,40) = 15.489, p
< 0.001; “Sessions”: F(6,240) = 3.506, p = 0.002; and “Treatment” × “Sessions” interaction, F(24,240) = 5.745, p < 0.001). In comparison to the
vehicle treatment, all three doses of olanzapine, but not chlordiazepoxide, significantly inhibited the acquisition of avoidance responding (Tukey Post hoc Tests: VEH vs. OLZ 0.5, 1.0, and 2.0 mg/kg, ps
< 0.001; VEH vs. CDP, p = 0.853). The three doses of olanzapine did
not differ in their magnitude of inhibition during the drug test days
(Tukey Post hoc Tests: OLZ 0.5 vs. OLZ 1.0, p = 0.988, OLZ 1.0 vs.
OLZ 2.0, p = 1.000, OLZ 0.5 vs. OLZ 2.0, p = 0.973), indicating a very
similar level of anti-“psychotic” efficacy at these doses. Figure 7B
shows the number of conditioned avoidance responses in the three
drug-free and CS-alone test days. The three olanzapine-treated
groups still exhibited significantly lower numbers of avoidances than
the vehicle group (VEH vs. OLZ 2.0, p = 0.032, vs. OLZ 1.0, p = 0.023,
vs. OLZ 0.5, p = 0.002) and the chlordiazepoxide group (CDP vs.
OLZ 2.0, p = 0.001, vs. OLZ 1.0, p = 0.001, and vs. OLZ 0.5, p < 0.001).
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Olanzapine and chlordiazepoxide inhibited the physiological fear
responses (e.g. body temperature increase or defecations). Figures 9A and
B depict the body temperature changes and amount of defecation
during the habituation phase, the training phase and the drug-free
test phase. Both measures were low during the habituation phase,
with no significant group difference detected (all ps > 0.05). During
the CAR training phase, there was a clear dose-dependent effect of
olanzapine treatment on body temperature change. Repeated Measures ANOVAs revealed a significant main effect of “Treatment”
(F(4,40) = 7.439, p < 0.001) and a significant main effect of “Sessions”
(F(6,240) = 3.50, p = 0.002), but no significant “Treatment” × “Sessions”
interaction (F(24,240) = 0.854, p = 0.665). Post hoc tests showed that
only the high dose of olanzapine significantly inhibited the body
temperature increase in comparison to vehicle (OLZ 2.0 vs. VEH: p
= 0.002). Consistent with the result from Experiment 2, chlordiazepoxide did not significantly decrease this measure (Tukey Post hoc,
CDP vs. VEH, p = 0.07). Low and medium doses of olanzapine were
also not effective (OLZ 0.5 vs. VEH, p = 0.999; OLZ 1.0 vs. VEH, p
= 1.00). No group difference was found during the three drug-free
CS-only test sessions (all ps > 0.05), suggesting that prior olanzapine treatment did not have a long-lasting effect on stress-induced
hyperthermia.
All three doses of olanzapine, as well as chlordiazepoxide, significantly decreased the amount of defecations across the 7 testing
days (Tukey Post hoc tests: VEH vs. OLZ 0.5, 1.0, and 2.0 mg/kg, p
< 0.019, 0.002 and 0.001 respectively, VEH vs. CDP, p < 0.035, onetailed). Once again, no group difference was found during the three
drug-free test CS-only test sessions (all ps > 0.05). These results suggest that olanzapine, like chlordiazepoxide, does possess an anxiolytic property in decreasing these particular conditioned fear
responses.
4. Discussion

Olanzapine did not affect the expression of 22-kHz ultrasonic vocalizations. As seen in Figure 8, few vocalizations were recorded during the habituation days. During the 7 CAR training days, only the
chlordiazepoxide group showed a progressive decrease on the number of 22-kHz calls, consistent with the finding from Experiment
2. However, the difference between the vehicle and the chlordiazepoxide groups was not as large as seen in Experiment 2. Importantly, none of the three doses of olanzapine inhibited the ultrasonic
vocalizations. Over all the olanzapine groups actually emitted more
22-kHz vocalization calls, a profile similar to that of the haloperidol
group, but dissimilar to that of clozapine, as seen in Experiment 2
(Repeated Measures ANOVAs: a significant main effect of “Treatment”: F(4,40) = 3.429, p = 0.017; “Sessions”: F(6,240) = 2.970, p = 0.008;
and “Treatment” × “Sessions” interaction, F(24,240) = 1.946, p = 0.007).
In the subsequent 3 drug-free test days, although the chlordiazepoxide rats showed less 22-kHz calls relative to the vehicle controls,
the difference was not significant (ps > 0.05). However, the chlordiazepoxide rats did show less 22-kHz calls than the olanzapine 0.5
mg/kg (day 1, p = 0.011; day 2: p = 0.014) and olanzapine 2.0 mg/
kg rats (day 1: p = 0.040).

The present study used two distinct behavioral models and evaluated the potential anxiolytic-like activity of typical anti-psychotic
haloperidol and atypicals clozapine and olanzapine, and compared
them with that of a classical anxiolyticc hlordiazepoxide. Table 2
summarizes the results from all experiments. Inspection of this table
reveals that clozapine and olanzapine show some similarities to
chlordiazepoxide in terms of their effects on a variety of fear measures indicative of anxiolytic property. Specifically, clozapine and
chlordiazepoxide, but not haloperidol, significantly attenuated the
shock conditioning-induced place aversion, decreased the amount
of defecations and the number of 22-kHz vocalizations. Clozapine
also reduced shock conditioning-induced hyperthermia. Similar to
clozapine, olanzapine also significantly decreased the amount of
defecations and reduced shock conditioning-induced hyperthermia,
but it did not inhibit 22-kHz vocalizations. Although it can be said
that clozapine, olanzapine and chlordiazepoxide all show some anxiolytic effects in the fear/anxiety measures in this study, some differences did exist. Clozapine significantly decreased the shock conditioning-induced hyperthermia but had no effect on the passive
avoidance latency, whereas chlordiazepoxide significantly decreased
the passive avoidance latency but had no effect on body temperature change. Olanzapine differed from clozapine and chlordiazepoxide in that it had no effect on 22-kHz ultrasonic vocalizations at
the three doses tested. Olanzapine’s anxiolytic property was mainly
manifested in its effect on hyperthermia and defecations, and this
effect seems limited to the drug test phase.
Our results also indicate that haloperidol does not seem to possess any anxiolytic-like property, as tested in these models, but may
instead possess an anxiogenic-like activity as it increased the passive
avoidance latency and the amount of defecations.
As mentioned in the Introduction section, evidence so far is variable in regards to the potential anxiolytic property of both typical
and atypical APDs. Behavioral studies have reported anxiolyticlike, anxiogenic-like and lack of effects with the use of typical or
atypical APDs in a broad range of animal models of fear or anxiety

Clozapine and Olanzapine Exhibit an Intrinsic Anxiolytic Property in Two Conditioned Fear Paradigms

559

560				

				

(Ichihara et al., 1988; Ishida-Tokuda et al., 1996; Kovacs and de Wied,
1978; Thiessen and Upchurch, 1981; Timmerman et al., 1990). One
contribution of the present study is that we employed two different behavioral models of fear/anxiety and multiple measures (both
behavioral as well as physiological) to examine this issue to ensure
that our results were not an artifact of a single model or measure.
Experiment 1 uses a composite passive avoidance and conditioned
place aversion task, with acute treatment commonly used in these
paradigms, to evaluate various conditioned fear responses, while
Experiments 2 and 3 use a two-way active avoidance model to simultaneously examine the anti-psychotic properties as well as the conditioned fear responses, using a repeated treatment regimen to best
mimic clinical features (Li et al., 2007). Results from Experiments 1
and 2 were consistent in showing that clozapine, but not haloperidol, has a strong anxiolytic activity as it reduced a number of shock
conditioning-induced fear responses, and results from Experiment
3 show that olanzapine possesses some anxiolytic properties as it
reduced shock conditioning-induced hyperthermia and defecations.
The fact that clozapine and olanzapine share certain anxiolytic effects
with chlordiazepoxide further strengthens this conclusion. The anxiolytic activity of clozapine or olanzapine does not seem to be due to
their effects on motor functions because rats were tested in the drugfree condition, and measurements such as the passive avoidance
latency, body temperature change, and defecations are independent
of the animals’ motor ability. This activity could not simply be attributed to their action on constipation (Bhana et al., 2001; Sachdev and
Saharov, 1998) or core body temperature (Millan et al., 1995; Salmi
et al., 1994) either, because this anxiolytic effect was observed even
when the treatment was stopped. We do not think the anxiolytic-like
activity of clozapine, olanzapine and chlordiazepoxide can be attributed to the drug effects on associative learning and memory specifically employed in fear conditioned tasks; however, some studies have shown that anti-psychotics impair learning and memory
on various other tasks in rodents. Skarsfeldt (1996) found that several typical and atypical anti-psychotics impaired spatial learning in
the Morris water maze, while other studies have found atypicals to
cause significant impairment of performance on the radial arm maze
and in the passive avoidance test (Ortega-Alvaro et al., 2006, Ishiyama et al., 2007). However, this memory impairment effect may not
completely account for our results. Clozapine and chlordiazepoxidetreated rats acquired the CS-US association as evidenced by the fact
that all groups of rats showed a significant increase in defecations on
the test day when they were being placed back into the environment
where they had received the shock (Experiment 1), and while haloperidol significantly impaired the acquisition of avoidance responding, it did not impair the conditioned fear responses. This conclusion
is also consistent with other studies showing that APDs generally
do not impair the learning or even expression of associative conditoning (Anisman et al., 1982; Beninger et al., 1980; Li et al., 2004). Li
et al. (2007) also found that after repeated haloperidol or olanzapine
treatment in the conditioned avoidance response paradigm animals
were able to recover avoidance responding after the treatment was

Mead, Li & Kapur in Pharmacology, Biochemistry and Behavior 90 (2008)

stopped, suggesting that both drugs do not affect the memory of
responding to the CS, but merely inhibit the motivation to respond.
Our results are also consistent with the finding showing that chlordiazepoxide affects declarative memory only, but does not disrupt
procedural memory (Fang et al., 1987; Nissen et al., 1987). In the current study the fear conditioned tasks are concerned with emotional
memory, rather than spatial learning or memory, which may explain
the conflicting results that exist. Due to these dissociations found
between the anxiolytic effect and memory, the anxiolytic activity of
clozapine and chlordiazepoxide may be separated from any possible
effect on learning and memory.
Although there is a suggestion that atypical APDs are better than
typicals in alleviating psychotic fear or anxiety, evidence on this
issue is still controversial. Most studies either did not directly compare atypicals to typicals (DeVry et al., 1993; Frye and Seliga, 2003)
or did not find any difference between the two (Fernandez-Tome et
al., 1979; Inoue et al., 1996; Rasmussen et al., 2001). Even in studies
that demonstrate atypicals show a superior anxiolytic effect (Siemiatkowski et al., 2001), it is not clear whether the observed superiority
is independent of the irreduced liability to produce akathisia (which
may look like anxiety) or the intrinsic anxiolytic effects. The second
contribution of the present study is that we carefully matched the
anti-psychotic efficacy of haloperidol with clozapine in Experiments
1 and 2, and with olanzapine in Experiment 3, thus ensuring that
they were compared under the same conditions so that any behavioral difference between the two cannot be attributed to the influence from their intrinsic anti-psychotic effect. The way we achieved
this was by using a dose for each drug that produced a comparable level of disruption on avoidance responding (Li et al., 2004).
The approach is justified by the well documented fact that avoidance responding is a reliable behavioral index of anti-psychotic efficacy (Wadenberg and Hicks, 1999), and the potency of a drug in the
avoidance responding test correlates well with its clinical potencies
(Arnt, 1982). Our results clearly show that under the current experimental conditions, clozapine and olanzapine are indeed superior in
alleviating a variety of fear-related responses when compared with
haloperidol.
The 22-kHz USVs are often observed when rats are exposed to
aversive situations (Antoniadis and McDonald, 1999; Burgdorf et
al., 2001; Wohr et al., 2005). Previous studies have shown that anxiolytics such as diazepam and chlordiazepoxide reduce the number
of 22-kHz calls (Vivian and Miczek, 1993). The effects of anti-psychotics on this measure are inconsistent, with some studies reporting reducing effects (DeVry et al., 1993; Molewijk et al., 1995), some
reporting no change (Bartoszyk, 1998), and others reporting an
enhancing effect (Siemiatkowski et al., 2001; Thiessen and Upchurch,
1981). Our clozapine and chlordiazepoxide results were consistent
with the literature. The finding that olanzapine failed to decrease
this measure was inconsistent with Siemiatkowski et al. (2001), who
reported that acute treatment with olanzapine (1.0 mg/kg) reduced
the pre-shock contextual vocalizations and tended to diminish the
post-shock ultrasonic vocalizations. The exact causes of this discrep-
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ancy are not clear, possibly due to the methodological differences
(rat strains: SD vs. Wistar; behavioral tasks: active avoidance vs. contextual fear conditioning, etc.).
The neurobiological mechanism(s) of the anxiolytic action of clozapine and olanzapine is poorly understood. Little work has directly
examined this issue. Recently, there has been indirect evidence suggesting that the effects of clozapine on allopregnanolone, a metabolite of progesterone, may be responsible for its anxiolytic effect. In
2003 and 2006, Marx et al. found that clozapine and olanzapine can
dose-dependently increase allopregnanolone in the rat cerebral cortex and hippocampus (Marx et al., 2006a; Marx et al., 2006b; Marx
et al., 2003). Since allopregnanolone acts as a positive modulator of
the GABA (A) receptor (Majewska, 1990), and shows a strong anxiolytic effect in the elevated plus-maze task and the Geller-Seifter
conflict test (Akwa et al., 1999; Bitran et al., 2000; Brot et al., 1997), it
is therefore possible that clozapine or olanzapine-induced elevations
in allopregnanolone may contribute to their anxiolytic-like effect.
Using these models and specific pharmacological agents will allow
one to parse out which of clozapine and olanzapine’s properties are
critical for thse anxiolytic effects and whether they are completely
dissociable from its anti-psychotic efficacy.
Results from the present report also suggest interesting behavioral
dissociations among haloperidol, clozapine, olanzapine and chlordiazepoxide with regards to their effects on two categories of conditioned fear responses (e.g. active vs. reactive). Conditioned fear
responses such as freezing, passively avoiding a “shocked” environment, or increasing the body temperature, number of 22-kHz USVs, or
defecations, are innate, reflexive species-typical responses to threats
and are expressed automatically in the presence of danger, thus they
are classified as “conditioned reactive fear responses.” Drug effects
on these measures may indicate an anxiolytic-like or anxiogenic-like
activity. In contrast, active avoidance to a fearful stimulus requires
animals to make an overt motor action and is a voluntary and intentional motor response to danger, thus it is deemed as “conditioned
active fear response” (Amorapanth et al., 2000). An action on the
active avoidance response is a well-established indicator of anti-psychotic-like activity (Wadenberg and Hicks, 1999). Collectively, our
results suggest that haloperidol, atypical APD blocking dopamine
D2 receptors, selectively disrupts active avoidance response but has
little or even an enhancing effect on conditioned reactive fear. Anxiolytic chlordiazepoxide, an agonist on benzodiazepine/GABA complex receptor system, inhibits conditioned reactive fear at doses that
have no effecton active avoidance consistent with its exclusive sedative hypnotic profile. Clozapine and olanzapine, the multi-receptor blocking atypical anti-psychotics, have inhibitory effects on both
types of fear responses, indicating a dual efficacy against both fear
and psychosis. It would be interesting to explore other APDs and
anxiolytics and see whether they conform to these dissociations.
The present study has several limitations. First, we did not examine the dose-response effect of clozapine or haloperidol. Only one
dose for each of these drugs was tested, though we attempted to
explore this issue with olanzapine. This issue will be addressed in
the next study. It is well-known that the same drug can have quite
different behavioral effects at different dosage levels (Murphy and
Feldon, 2000). It is thus possible that haloperidol might even show
an anxiolytic activity when tested at a lower dose. However, because
our haloperidol dose is considered to be clinically relevant in terms
of its effect on dopamine D2 occupancy and on avoidance responding (Kapur et al., 2003b), it could be said that at least haloperidol
has little anxiolytic effect at the clinically relevant doses. Second, we
did not examine how sensitive and reliable our models are in comparison to other established animal models of fear and anxiety such
as elevated plus-maze. Third, we only examined how anti-psychotic
treatment affects the acquisition of conditioned fear, not its retention and extinction.
In summary,the present study demonstrates that atypical APDs
such as clozapine and olanzapine do possess a certain degree of
anxiolyitic efficacy. This additional efficacy is not attributable to its
superior anti-psychotic effect or its favorable effects on motor func-
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tions or learning and memory processes. The findings also suggest
that the combined use of passive avoidance and active avoidance
conditioning models can be useful in better differentiating typical,
atypical anti-psychotics and anxiolytics. To some extent, this study
clarifies certain confusions in the literature regarding the intrinsic
anxiolytic property of both typical and atypical antipsychotics.
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